Healthy Debate Calls for Policy Changes to Combat Antibiotic Resistance, Citing Flawed Business Models
Healthy Debate, in an article by Anne Fortier and E. Richard Gold, highlights that combating rising antibiotic resistance requires new policies, not just new drugs. The authors argue that while scientific advancements in antibiotic development are possible, the current pharmaceutical business model is fundamentally at odds with the prudent use of these drugs. Antibiotics are most effective when used sparingly to delay resistance, which conflicts with a sales-volume-based business model. This misalignment has led to the bankruptcy of companies like Achaogen and Melinta, despite bringing new antibiotics to market for serious drug-resistant infections. The article points out that drug resistance was directly responsible for 1.14 million deaths in 2021 and was linked to nearly five million more, with projections indicating a worsening trend. The authors advocate for 'delinked payment' models, where governments pay a fixed fee for antibiotic availability rather than per dose, aligning financial incentives with ...